Top Stories

Latest News & Analysis

C+D's annual salary survey needs you

C+D needs your insights! Share your experiences in our annual Salary Survey. Take the survey now.

Pharmacists must not ‘directly engage’ patients in assisted dying debate

 
• By Kate Bowie

The UK chief pharmaceutical officers (CPhOs) have set boundaries around pharmacist involvement in the assisted dying debate, amid calls for a “clear” role for pharmacists in the Scottish assisted dying bill.

Repeat offender online pharmacy warned over weight loss POM ads

 
• By Ben Lee

The medicines regulator has ordered an online pharmacy to amend its advertising for medication “not licensed for weight loss” following a complaint, it has revealed.

Government to cut pharmacy business rates from 2026

 
• By Molly Bowcott

The government has introduced draft legislation to “permanently cut business rates” for pharmacies and other high-street retailers from 2026 as it continues to come under fire over its recent budget tax hikes, it has revealed.

US pharmacies endorse ‘vaccine-sceptic’ new health sec RFK Jr

 
• By Molly Bowcott

A US community pharmacy body has welcomed the nomination of Robert F Kennedy Jr as health secretary under Donald Trump’s new administration, despite his controversial comments about vaccines.

Superdrug agrees to PDA Union’s bargaining unit proposals

 
• By Molly Bowcott

The PDA has taken the next step in securing union recognition at Superdrug after the company agreed to its proposed bargaining unit, despite previous reservations.

Opinion

Editorial: Pharmacy is a perpetual victim of someone else’s confusion

 
• By James Halliwell

Labour – remarkably – still has some way to go before it plumbs the depths reached by the Conservatives. But it is trying.

opinion

From a banker: What the budget means for community pharmacy

 
• By Alexandra Rice

This broad investment in the NHS will be most impactful, but only if matched with effective community care services on the frontline...

We can’t Wegovy our way out of the diabesity crisis...

 
• By Graham Phillips

"The GLP1s are relatively new and are being rolled-out as scale. We have no idea what damage 20 years of drug-induced hyper-incretin-aemia may cause, but the history of abandoned slimming drugs tells me it won’t end well."

England’s pharmacy market analysed: “A few drugs can make the difference in making a profit.”

 
• By Paul Steet

With the NHS under significant pressure, there’s a real opportunity here for pharmacies to support overstretched GP and hospital services - if they’re given the proper support.